Pegylated liposomal doxorubicin HCl (Caelyx) in combination with sandostatin LAR as salvage therapy in patients with small cell lung cancer
K. N. Syrigos, E. Hatzidarellis, A. G. Charpidou, C. Alamara, K. Pantazopoulos, F. Skotti, D. Antoniou, N. Georgatou (Athens, Greece)
Source: Annual Congress 2005 - Treatment of lung cancer
Session: Treatment of lung cancer
Session type: Thematic Poster Session
Number: 593
Disease area: Respiratory infections
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. N. Syrigos, E. Hatzidarellis, A. G. Charpidou, C. Alamara, K. Pantazopoulos, F. Skotti, D. Antoniou, N. Georgatou (Athens, Greece). Pegylated liposomal doxorubicin HCl (Caelyx) in combination with sandostatin LAR as salvage therapy in patients with small cell lung cancer. Eur Respir J 2005; 26: Suppl. 49, 593
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Pegylated liposomal doxorubicin compared with traditional doxorubicin in combination chemo-radiotherapy for small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 465s Year: 2002
Effectivity of chemotherapy regimen included carboplatin, ifosfamide, etoposide with or without adding interferon alpha 2a in treatment of patients with small cell lung carcinoma Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
The effectiveness of vinorelbine plus cisplatin versus gemcitabine plus cisplatin in local advanced non small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 752s Year: 2006
Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer Source: Eur Respir J 2006; 27: 1183-1189 Year: 2006
Economic evaluation of gemcitabine plus cisplatin (GD) versus vinorelbine plus cisplatin plus Ifosfamide (NIP) in patients with locally advanced or metastatic non-small-cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003
First line treatment with gemcitabine plus cisplatine in non-small cell lung cancer: a comparison with etoposide plus cisplatin Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005
Sequential monochemotherapy: vepesid (VP16) and carboplatin (CBDCA) in the treatment of elderly patients with small cell lung cancer (SCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 395s Year: 2001
Non-small cell lung cancer treatment: chemotherapy combination gemcitabine – cisplatin – paclitaxel Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004
A study of paclitaxel in two dose combinations with carboplatin in the treatment of small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 319s Year: 2001
Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013
Treatment of advanced and metastatic non small cell lung carcinoma (NSCLC) with a new schedule of gemcitabine (GEM) plus cisplatin (CDDP) Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002
Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 301s Year: 2004
Comparison of vinorelbine containing dublet versus triplet schedule (vinorelbine cisplatin versus vinorelbine-ifosfamide cisplatin) in NSCLC Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001
Combination of erlotinib and bevacizumab in non small cell lung cancer patients Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
A phase II trial in patients with extensive disease small-cell lung cancer with irinotecan, carboplatin and etoposide regimen as a first line treatment Source: Eur Respir J 2006; 28: Suppl. 50, 781s Year: 2006
Phase II study of gemcitabine plus irinotecan as second-line chemotherapy in advanced non-small cell lung cancer Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009
A comparison between the toxic side effects of adriamycin, cyclophosphamide, and etoposide (ACE) and carboplatin with etoposide (CbE) in the treatment of small cell lung cancer (SCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 65s Year: 2003
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer Source: Eur Respir J 2015; 46: 219-229 Year: 2015
Cisplatin and docetaxel induction chemotherapy results Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005
Phase I trial of pemetrexed, carboplatin and sorafenib as first-line treatment in patients with metastatic NSCLC Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010